TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34096986

Group type: EXPERIMENTAL
Intervention: Children of WWE taking ASMs
Number of subjects: 292

Group type: COMPARATOR
Intervention: Children of healthy women
Number of subjects: 292
Study: 34097055

Group type: EXPERIMENTAL
Intervention: Accelerometer monitoring of physical activity levels
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery scores
Number of subjects: 15
Study: 34097071

Group type: EXPERIMENTAL
Intervention: Dexamethasone-corticotropin-releasing hormone (Dex/CRH) test
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (women without depression)
Number of subjects: 40
Study: 34097100

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI) at a dose of 35 mg/m²
Number of subjects: 43
Study: 34097307

Group type: EXPERIMENTAL
Intervention: Postoperative intensity-modulated radiotherapy (IMRT)
Number of subjects: 76
Study: 34097449

Group type: EXPERIMENTAL
Intervention: Probabilistic readjudication of hospitalization events
Number of subjects: 0
Study: 34097852

Group type: EXPERIMENTAL
Intervention: KTE-X19
Number of subjects: 71
Study: 34098066

Group type: EXPERIMENTAL
Intervention: Deep learning model using resting-state and task-based fMRI datasets
Number of subjects: 0
Study: 34098740

Group type: EXPERIMENTAL
Intervention: Female sex (as an independent variable)
Number of subjects: 16821
Study: 34098895

Group type: EXPERIMENTAL
Intervention: K-001 (1350 mg to 2160 mg, administered twice daily in four-week cycles)
Number of subjects: 12
Study: 34098897

Group type: EXPERIMENTAL
Intervention: Micro Hand S robot-assisted TME (RTME)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Laparoscopic TME (LTME)
Number of subjects: 105
Study: 34098916

Group type: EXPERIMENTAL
Intervention: Key social network members (SNMs) identified by MSM
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Discussions about HIV and STI prevention with SNMs
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Discussions about HIV/STI prevention among trans women
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Perceived support for condom use among MSM SNMs
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Perceived support for HIV/STI testing among trans women SNMs
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Support for partner STI notification among MSM SNMs
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Support for partner STI notification among trans women SNMs
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Reported condomless anal intercourse (CAI)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Association between SNM characteristics and CAI
Number of subjects: 565
Study: 34098967

Group type: COMPARATOR
Intervention: Patients without treatment limitation
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Patients with any treatment limitation
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Treatment limitations (PTL)
Number of subjects: 526
Study: 34098979

Group type: EXPERIMENTAL
Intervention: Arm-leg pulley system
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 8
Study: 34098992

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34099056

Group type: EXPERIMENTAL
Intervention: 12-week dietary restriction protocol (300 kcal/day reduction)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (metabolic status maintenance)
Number of subjects: 29
Study: 34099131

Group type: EXPERIMENTAL
Intervention: CPAP titrated to match pleural pressure (6 ± 2 cmH₂O)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (normal BMI participants)
Number of subjects: 12
Study: 34099325

Group type: EXPERIMENTAL
Intervention: gp120 envelope protein variants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platform development strategy
Number of subjects: 0
Study: 34099518

Group type: EXPERIMENTAL
Intervention: Tubeless, on-body automated insulin delivery system with customizable glycemic targets
Number of subjects: 235

Group type: COMPARATOR
Intervention: Usual insulin regimen (2-week standard therapy phase)
Number of subjects: 235
Study: 34099530

Group type: EXPERIMENTAL
Intervention: Manganese-enhanced MRI (MEMRI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Late gadolinium enhancement (LGE)
Number of subjects: 40
Study: 34099718

Group type: EXPERIMENTAL
Intervention: neoadjuvant eribulin therapy
Number of subjects: 35
Study: 34099923

Group type: EXPERIMENTAL
Intervention: HIV positive individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: People without HIV
Number of subjects: 0
Study: 34099953

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Connective tissue techniques
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard rehabilitation protocol (Control)
Number of subjects: 34
Study: 34100024

Group type: EXPERIMENTAL
Intervention: Presence of SARS-CoV-2 antibodies
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Viral RNA levels
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Virus-targeted treatment and prevention strategies
Number of subjects: 204
Study: 34100124

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LU) examination
Number of subjects: 877

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 877
Study: 34100292

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34100558

Group type: EXPERIMENTAL
Intervention: Early postnatal discharge
Number of subjects: 9409
Study: 34100767

Group type: EXPERIMENTAL
Intervention: SleepFit application (v2.0)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SleepFit application (from alpha to v1.0)
Number of subjects: 56
Study: 34101002

Group type: EXPERIMENTAL
Intervention: Treatment with LCZ696 vs. enalapril
Number of subjects: 7156
Study: 34101090

Group type: EXPERIMENTAL
Intervention: RNA-pulsed dendritic cell vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RNA-loaded nanoparticle vaccines
Number of subjects: 0
Study: 34101138

Group type: EXPERIMENTAL
Intervention: 0.07 mg LOR
Number of subjects: 231

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 231
Study: 34101502

Group type: EXPERIMENTAL
Intervention: Procedural intervention for uterine fibroids
Number of subjects: 0
Study: 34101537

Group type: EXPERIMENTAL
Intervention: Ask Suicide-Screening Questions (ASQ)
Number of subjects: 1324

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ)
Number of subjects: 1324
Study: 34101626

Group type: EXPERIMENTAL
Intervention: DS003 (BMS-599793)
Number of subjects: 0
Study: 34101701

Group type: EXPERIMENTAL
Intervention: Sexual orientation concealment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internalized homophobia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transactional sex
Number of subjects: 0
Study: 34102018

Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (SV) for 3 months
Number of subjects: 118
Study: 34102349

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg orally once daily (reduced to 280 mg/d with voriconazole)
Number of subjects: 19
Study: 34102857

Group type: EXPERIMENTAL
Intervention: Regional denervation volume
Number of subjects: 0

Group type: COMPARATOR
Intervention: Global parameters of sympathetic innervation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine analog imaging
Number of subjects: 0
Study: 34102902

Group type: EXPERIMENTAL
Intervention: 32-mm metal head
Number of subjects: 96

Group type: COMPARATOR
Intervention: 36- to 44-mm metal head
Number of subjects: 96
Study: 34103005

Group type: EXPERIMENTAL
Intervention: GEnetic Syntax Score (GESS) risk prediction algorithm based on genetic markers and clinical information.
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Next generation sequencing (NGS) technology to genotype 228 SNPs associated with CAD.
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: SYNTAX score calculation for assessment of CAD severity based on angiographic findings.
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Follow-up for one year to record major adverse cardiovascular events.
Number of subjects: 1080
Study: 34103022

Group type: EXPERIMENTAL
Intervention: Improved chicken management practices
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Having a chicken coop
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Enclosed chicken coop
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Coops that were enclosed, had fencing, and were located further from homes
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Direct observations of chicken coops
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Presence of livestock and domestic animals inside homes
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: In-depth interviews with child caregivers
Number of subjects: 973
Study: 34103176

Group type: EXPERIMENTAL
Intervention: T2DM group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 34103352

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity (dMMR cohort)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity (pMMR cohort)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Durvalumab (dMMR cohort)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Durvalumab (pMMR cohort)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Durvalumab (both cohorts)
Number of subjects: 71
Study: 34103993

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional perioperative care program
Number of subjects: 130
Study: 34104033

Group type: EXPERIMENTAL
Intervention: Blue light therapy (BLT) for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amber light therapy (ALT) for 6 weeks
Number of subjects: 28
Study: 34104395

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no zoledronic acid)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups (zoledronic acid and control)
Number of subjects: 76
Study: 34104466

Group type: EXPERIMENTAL
Intervention: Polar V800
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: eMotion Faros 360
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: TomTom heart rate monitor
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Adidas miCoach Smart Run
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine electrocardiograms
Number of subjects: 144
Study: 34104849

Group type: EXPERIMENTAL
Intervention: Combined EPA+DHA intake (median daily intake 70 mg, IQR: 32, 145 mg)
Number of subjects: 7365
Study: 34104852

Group type: EXPERIMENTAL
Intervention: LP + Bar
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HP
Number of subjects: 8

Group type: COMPARATOR
Intervention: LP
Number of subjects: 8
Study: 34104878

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) therapy, transfusion in three doses of 3 mL/kg of recipient body weight at 2-day intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) therapy
Number of subjects: 0
Study: 34105200

Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA)
Number of subjects: 13322
Study: 34105303

Group type: EXPERIMENTAL
Intervention: bDMARDs initiated within 3 months of baseline assessment
Number of subjects: 400

Group type: COMPARATOR
Intervention: bDMARDs initiated after 3 months from baseline assessment
Number of subjects: 400

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 400
Study: 34105312

Group type: EXPERIMENTAL
Intervention: Early combination plan (DMARD and biologic started together)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Step-up plan (initial nonbiologic DMARD monotherapy)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Biologic first plan (biologic monotherapy)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Early combination plan
Number of subjects: 400

Group type: COMPARATOR
Intervention: Step-up plan
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 400
Study: 34105902

Group type: EXPERIMENTAL
Intervention: Inpatient trauma treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy control group (n = 37)
Number of subjects: 23
Study: 34106085

Group type: EXPERIMENTAL
Intervention: Wireless home blood pressure monitoring
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Wireless home blood pressure monitoring with financial incentives
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care (nonwireless home blood pressure monitoring)
Number of subjects: 42
Study: 34106597

Group type: EXPERIMENTAL
Intervention: Non-cohort registry respondents (AF patients who did not consent for 24 month follow up)
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Cohort registry respondents (AF patients who consented for 24 month follow up)
Number of subjects: 1568
Study: 34107166

Group type: EXPERIMENTAL
Intervention: Napabucasin (240 mg twice daily; days 1-11)
Number of subjects: 30
Study: 34107398

Group type: EXPERIMENTAL
Intervention: JNJ-63733657 (tau mAb)
Number of subjects: 0
Study: 34107506

Group type: EXPERIMENTAL
Intervention: Parent-child dyads, siblings, and parent-parent dyads during different time segments of the week.
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Total family physical activity during late weekdays and weekends.
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Light physical activity and walking behaviors.
Number of subjects: 1576
Study: 34107510

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 36

Group type: COMPARATOR
Intervention: Men
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both men and women
Number of subjects: 36
Study: 34107742

Group type: EXPERIMENTAL
Intervention: Microvascular disease (MVD) defined as the presence of ≥1 of nephropathy, retinopathy, or neuropathy at baseline (n=1424, 34.8%)
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: Nephropathy (type of MVD)
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: Retinopathy (type of MVD)
Number of subjects: 4095

Group type: EXPERIMENTAL
Intervention: Neuropathy (type of MVD)
Number of subjects: 4095
Study: 34107771

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplant (alloBMT) with continuous antiretroviral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative viral outgrowth assay
Number of subjects: 0
Study: 34107841

Group type: EXPERIMENTAL
Intervention: 10-weeks of progressive resistance training (3 sessions per week, 4 lower body exercises, 2-4 sets of 8-15 repetitions at 60-75% of 1-repetition maximum)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10-weeks of progressive resistance training
Number of subjects: 18
Study: 34107914

Group type: EXPERIMENTAL
Intervention: Simulation-based nursing intervention including usual care, an informational booklet from NCI, and three meetings with a nurse interventionist during radiation treatment followed by a booster call two weeks posttreatment.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care and an informational booklet from NCI.
Number of subjects: 180
Study: 34108134

Group type: EXPERIMENTAL
Intervention: GAPS-EUS assessment tool
Number of subjects: 22
Study: 34108167

Group type: EXPERIMENTAL
Intervention: CT perfusion (CTP) imaging at the time of first imaging on hospital admission
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bedside clinical assessment for brainstem function
Number of subjects: 200
Study: 34108168

Group type: EXPERIMENTAL
Intervention: IA injection of triamcinolone acetonide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline urinary tests and dried blood spot tests
Number of subjects: 20
Study: 34108929

Group type: EXPERIMENTAL
Intervention: Intravitreal Gene Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural History
Number of subjects: 0
Study: 34108964

Group type: EXPERIMENTAL
Intervention: Lentiviral vectors pseudotyped with Influenza B hemagglutinins (IBV PV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical methods (hemagglutination inhibition assay and serial radial hemolysis assay)
Number of subjects: 0
Study: 34109185

Group type: EXPERIMENTAL
Intervention: Pre-operative/Neoadjuvant Therapy and Vascular Debranching followed by Resection
Number of subjects: 0
Study: 34109223

Group type: EXPERIMENTAL
Intervention: Serum Uric Acid levels
Number of subjects: 0
Study: 34109243

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34109306

Group type: EXPERIMENTAL
Intervention: C-IVIG (0.15 g/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: C-IVIG (0.20 g/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: C-IVIG (0.25 g/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: C-IVIG (0.30 g/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: C-IVIG (all dosage arms)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: C-IVIG
Number of subjects: 50
Study: 34109484

Group type: EXPERIMENTAL
Intervention: FCN-437c 50 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: FCN-437c 100 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: FCN-437c 200 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: FCN-437c 300 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: FCN-437c 450 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: FCN-437c (all doses)
Number of subjects: 17
Study: 34109515

Group type: EXPERIMENTAL
Intervention: WBRT + sorafenib (200 mg daily for 21 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: WBRT
Number of subjects: 13
Study: 34109624

Group type: EXPERIMENTAL
Intervention: HC-1119 at doses of 40, 80, 160, and 200 mg/day (part A)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HC-1119 at doses of 80 and 160 mg (part B)
Number of subjects: 43
Study: 34110001

Group type: EXPERIMENTAL
Intervention: Endometrial injury (intentional damage to the endometrium)
Number of subjects: 8786

Group type: COMPARATOR
Intervention: Control (no intervention or a sham procedure)
Number of subjects: 8786
Study: 34110033

Group type: EXPERIMENTAL
Intervention: D'Amico low risk
Number of subjects: 21646

Group type: EXPERIMENTAL
Intervention: D'Amico intermediate risk
Number of subjects: 21646

Group type: EXPERIMENTAL
Intervention: D'Amico high risk
Number of subjects: 21646

Group type: EXPERIMENTAL
Intervention: Gleason Grade Group I (GGG I)
Number of subjects: 21646

Group type: EXPERIMENTAL
Intervention: Gleason Grade Group II (GGG II)
Number of subjects: 21646

Group type: EXPERIMENTAL
Intervention: Gleason Grade Group III to V (GGG III-V)
Number of subjects: 21646

Group type: EXPERIMENTAL
Intervention: ≥cT2
Number of subjects: 21646
Study: 34110383

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg/d for 3 cycles) followed by combination with venetoclax (ramp-up to 400 mg/d for 24 cycles)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax
Number of subjects: 80
Study: 34110489

Group type: EXPERIMENTAL
Intervention: Treatment for progressive well-differentiated NETs
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Presence of ≥ 5 bone metastases
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Non-gastroenteropancreatic (non-GEP) NETs
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Development of interim ascites
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Chromogranin A of ≥ 4 × upper limit of normal (ULN)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Pre-existing ascites
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Liver metastases involving greater than 50% liver volume
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Existence of unusual metastatic locations
Number of subjects: 47
Study: 34110505

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reslizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 0
Study: 34110605

Group type: EXPERIMENTAL
Intervention: secukinumab 150/300 mg
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: etanercept
Number of subjects: 2401

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2401
Study: 34111495

Group type: EXPERIMENTAL
Intervention: Cerebral blood flow (CBF) and functional connectivity strength (FCS) measurements
Number of subjects: 0
Study: 34111887

Group type: EXPERIMENTAL
Intervention: Fluorescence lifetime imaging ophthalmoscope (Heidelberg Engineering)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Imaging artifacts (too short image acquisition time, insufficient illumination, ocular surface problems, image defocus)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Prior use of systemic or topical fluorescein
Number of subjects: 5
Study: 34112151

Group type: EXPERIMENTAL
Intervention: Leadership support and organizational structure
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Contextual factors
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Leadership involvement
Number of subjects: 23
Study: 34112154

Group type: EXPERIMENTAL
Intervention: Nurse-led empowering education using teach-back method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study: 34112181

Group type: EXPERIMENTAL
Intervention: Specific carbohydrate diet
Number of subjects: 22
Study: 34112230

Group type: EXPERIMENTAL
Intervention: Surgery for acute TAAD
Number of subjects: 0
Study: 34112454

Group type: EXPERIMENTAL
Intervention: PREDICT-TAVR score (6-item score including blood hemoglobin, serum iron concentrations, oral anticoagulation, dual antiplatelet therapy, common femoral artery diameter, and creatinine clearance)
Number of subjects: 5185

Group type: EXPERIMENTAL
Intervention: External validation of PREDICT-TAVR score
Number of subjects: 5185

Group type: EXPERIMENTAL
Intervention: PREDICT-TAVR score quartiles
Number of subjects: 5185
Study: 34112625

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI (DW-MRI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SUV-max, SUL-peak, SUV-mean
Number of subjects: 10
Study: 34112707

Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg twice daily for 12 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Observation group (nonrandomized control)
Number of subjects: 43